title: alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria.
abstract: Natural killer T (NKT) cells are a unique population of lymphocytes that coexpress a semiinvariant T cell and natural killer cell receptors, which are particularly abundant in the liver. To investigate the possible effect of these cells on the development of the liver stages of malaria parasites, a glycolipid, alpha-galactosylceramide (alpha-GalCer), known to selectively activate Valpha14 NKT cells in the context of CD1d molecules, was administered to sporozoite-inoculated mice. The administration of alpha-GalCer resulted in rapid, strong antimalaria activity, inhibiting the development of the intrahepatocytic stages of the rodent malaria parasites Plasmodium yoelii and Plasmodium berghei. The antimalaria activity mediated by alpha-GalCer is stage-specific, since the course of blood-stage-induced infection was not inhibited by administration of this glycolipid. Furthermore, it was determined that IFN-gamma is essential for the antimalaria activity mediated by the glycolipid. Taken together, our results provide the clear evidence that NKT cells can mediate protection against an intracellular microbial infection.
authors.affiliation: Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, NY 10010, USA.
authors.forename: G
authors.initials: G
authors.lastname: Gonzalez-Aseguinolaza
authors.forename: C
authors.initials: C
authors.lastname: de Oliveira
authors.forename: M
authors.initials: M
authors.lastname: Tomaska
authors.forename: S
authors.initials: S
authors.lastname: Hong
authors.forename: O
authors.initials: O
authors.lastname: Bruna-Romero
authors.forename: T
authors.initials: T
authors.lastname: Nakayama
authors.forename: M
authors.initials: M
authors.lastname: Taniguchi
authors.forename: A
authors.initials: A
authors.lastname: Bendelac
authors.forename: L
authors.initials: L
authors.lastname: Van Kaer
authors.forename: Y
authors.initials: Y
authors.lastname: Koezuka
authors.forename: M
authors.initials: M
authors.lastname: Tsuji
mesh_terms: D000818:Animals; D018949:Antigens, CD1 / Q000276:immunology; D000962:Antimalarials / Q000008:administration & dosage / Q000494:pharmacology*; D005699:Galactosylceramides / Q000008:administration & dosage / Q000494:pharmacology*; D007371:Interferon-gamma / Q000276:immunology; D018664:Interleukin-12 / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D008099:Liver / Q000469:parasitology; D008213:Lymphocyte Activation / Q000187:drug effects* / Q000276:immunology; D008288:Malaria / Q000276:immunology* / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010962:Plasmodium berghei / Q000187:drug effects / Q000276:immunology*; D010967:Plasmodium yoelii / Q000187:drug effects / Q000276:immunology*; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
chemical_list: D018949:Antigens, CD1; D000962:Antimalarials; D005699:Galactosylceramides; D016693:Receptors, Antigen, T-Cell, alpha-beta; D018664:Interleukin-12; D007371:Interferon-gamma